Newsletter

Benfobel S: Korea’s First High-Content Active Vitamin for Peripheral Neuropathy Treatment and Liver Enhancement

Chong Kun Dang Launches Groundbreaking Vitamin Supplement ‘Benfobel S’ Chong Kun Dang, a leading pharmaceutical company in Korea, has introduced ‘Benfobel S,’ the country’s first high-content active vitamin. This innovative supplement boasts 60 mg of mecobalamin, a crucial ingredient for treating peripheral neuropathy, as well as ursodeoxycholic acid (UDCA), known for its liver-enhancing properties. The […]

Patients Struggle with Lack of Disease Understanding and Delayed Diagnosis in Diabetic Peripheral Neuropathy

Patients Suffering from Diabetic Peripheral Neuropathy Lament Lack of Awareness and Understanding Pain caused by diabetes often goes unnoticed by patients until it becomes another ailment altogether. Referred to as diabetic peripheral neuropathy, this condition occurs when diabetic patients are exposed to high blood sugar for extended periods, leading to dysfunction of the peripheral nerves. […]

Chong Kun Dang Launches Korea’s First High-Content Active Vitamin ‘Benfobel S’ with Improved Physical Fatigue and Liver Function

Chong Kun Dang, a leading pharmaceutical company in Korea, has recently introduced a groundbreaking product called ‘Benfobel S’. This innovative high-content active vitamin contains 60 mg of mecobalamin, a potent ingredient for treating peripheral neuropathy, and ursodeoxycholic acid (UDCA), which improves liver function. Benfobel S stands out from existing products by its enhanced vitamin B […]

‘Diabetes’, which causes neuropathy, ‘blood sugar control’ is essential to prevent complications [쉬운 신경질환사전]

[쉬운 신경질환사전]is a series of articles designed by neurologist Hanseung Lee (Herbal Neurology Clinic) and Hidak on the topic of neurological diseases in everyday life. Common but vague symptoms such as ‘eyelid tremors’, ‘dizziness’, ‘drip hands and feet’, and ‘various headaches’ are explained in a way that is easy for the public to understand. Diabetes […]

ADCETRIS becomes the first-line treatment for Hodgkin’s lymphoma?

Image source: EHA official website [메디칼업저버 박선재 기자] The results of a six-year follow-up study that showed that the addition of ADCETRIS (ingredient: brentuximab vedotin) to conventional chemotherapy for classical Hodgkin lymphoma improved overall survival (OS) was published. As a result of this study, interest is growing whether Takeda Pharmaceutical’s ADCETRIS (ingredient name: brentuximab vedotin), […]